Imunon

Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus on the bottom line, reporting a net loss of $2.8M compared to the anticipated $3.9M. GAAP EPS of -$0.54 outperformed the expected -$1.04, driven largely by disciplined operating expense management and lower-than-expected G&A costs. Clinical momentum remains strong with the Phase 3 OVATION 3 study enrollment exceeding planning assumptions, following compelling Phase 2 overall survival data (+14.7 months).